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Background: Although some studies have reported a potential connection between ovulation induction therapy
(OIT) and malignant ovarian diseases, the results have been inconclusive. In the present study, we sought to
determine whether women undergoing OIT at our in vitro fertilization (IVF) clinic, especially those with severe
ovarian hyperstimulation syndrome (OHSS) and suspicious cytologic findings, were at risk for developing malignant
ovarian tumours after treatment.
Methods: Patients who underwent OIT at our IVF clinic were enrolled in this study and assessed for any evidence
of malignant ovarian tumours. Patients who developed severe OHSS as a result of OIT were treated with a
culdocentesis. Cells from the ascitic fluid were cytologically scored for abnormality and malignancy. Peripheral
blood samples were obtained from patients with severe OHSS to determine serum levels of the tumour markers
(CA-125 and HE4) that were used to calculate the Risk for Ovarian Malignancy Algorithm (ROMA) index.
Results: Follow-up data were available for 1,353 of the 1,587 patients (85%) who underwent OIT at our IVF clinic
between January 2006 and December 2012. Twenty-three patients (1.4%) were hospitalized with OHSS. Culdocentesis
was performed 16 times in nine patients with severe OHSS (age range, 23–34 years; mean, 27.1 years). Although
cytological examination of the ascitic cells of these patients suggested malignant ovarian neoplasia, over the course of
the observation period, the ovarian volume gradually decreased and became normal. Subsequent cytological and
histological examinations failed to find evidence of any malignant tumours in these nine patients. None of the 1,353
participants who underwent OIT developed any malignant ovarian tumours during the study period. Moreover, none
of the 462 patients who were in our ovarian tumour registry were also participants in the IVF program.
Conclusions: The presence of atypical cells in the ascitic fluid of women with severe OHSS does not likely indicate
malignancy; therefore, radical surgical intervention is not justified. The risk of malignancy is minimal shortly after OIT. At
our centre, OIT has not been associated with any cases of ovarian tumour.Background
Ovarian hyperstimulation syndrome (OHSS) is an iatro-
genic complication of ovarian induction therapy (OIT)
that may be observed after stimulation with human
chorionic gonadotropin or after the spontaneous lutein-
izing hormone peak. In OHSS, increased vascular per-
meability leads to subsequent fluid accumulation,* Correspondence: dr.hatzipetros@yahoo.com
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distribution, and reproduction in any mediumespecially in the abdominal cavity [1], with symptoms
appearing 5 to 10 days after gonadotropin administra-
tion. The risk factors for OHSS include young age,
polycystic ovarian syndrome, and a medical history of
hyper-response to gonadotropins [2]. Early prediction of
OHSS is crucial for prompt treatment. Diagnostic mea-
sures for predicting OHSS include an antral follicle
count of ≥14 on a transvaginal ultrasound (82% sensi-
tivity and 89% specificity) [3] and a basal anti-Müllerian
hormone serum level of ≥ 3.5 ng/mL (90.5% sensitivity,
81.3% specificity) [4].tral Ltd. This is an Open Access article distributed under the terms of the
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guished by clinical signs and laboratory findings. Mild
OHSS is a relatively common side effect of controlled
ovarian stimulation that affects up to one-third of pa-
tients undergoing in vitro fertilization (IVF). Moderate
and severe forms of OHSS have a combined incidence
ranging from 3% to 8% [5]. The clinical consequences of
mild and moderate OHSS are very minor. However, se-
vere OHSS is a potentially life-threatening condition
with symptoms that include ovarian enlargement, hydro-
thorax, hemoconcentration, salt and water dysregulation,
oliguria, thromboembolic disease, and coagulation ab-
normalities. Approximately 1.4% of OHSS cases are se-
vere, and severe OHSS is associated with a mortality risk
of 1 in 450,000 to 500,000 [6].
Several studies have suggested a possible connection
between OIT and ovarian tumours. For example, re-
searchers have observed cases of struma ovarii [7],
folliculoma [8], serous papillary carcinoma [9], mucinous
cystadenoma [10], serous papillary cystadenoma [10], epi-
thelial ovarian carcinoma [11], and cystadenocarcinoma
[12] during and/or after OIT. In a case–control study
performed in Israel between 1990 and 1993, Shushan
et al. [13] concluded that OIT with human menopausal
gonadotropin might increase the risk of epithelial ovarian
malignancies, specifically borderline ovarian tumours.
However, in some studies, hyperstimulation-induced re-
versible histological changes may have been grouped with
malignant disease [14,15].
In light of the potential confounders present in previ-
ous data, further research is needed to clarify the rela-
tionship between OIT and ovarian malignancy. The aim
of this study was to determine whether women undergo-
ing OIT at our IVF clinic, especially those with severe
OHSS and suspicious cytologic findings, were at risk for
developing malignant ovarian tumours after treatment.
Cells from the ascitic fluid recovered from patients with
severe OHSS were characterized to determine if they
were cytologically abnormal and whether the cytology
indicated the presence of an ovarian malignancy.Methods
Patients and study design
This prospective study was approved by the University
of Pecs Institutional Ethical Review Board. Patients were
included in this study if they were treated with OIT at
the Clinical Centre of the University of Pecs Department
of Obstetrics and Gynaecology/Reproductive Centre be-
tween January 2006 and December 2012 and provided
their written informed consent to participate. Patients
were questioned in person or surveyed by a mailed ques-
tionnaire about any current or past treatments for malig-
nant ovarian tumours.Evaluation of the abdominal fluid
From January 2006 to December 2012, nine IVF clinic pa-
tients developed severe OHSS. Ovarian hyperstimulation
was classified into three grades according to the severity
of the symptoms, signs, and laboratory findings (Rizk and
Aboulghar, 1999). These patients were treated with stand-
ard drug therapies, including a macrolide, intravenous
fluids, clexane, and aspirin, as well as ultrasound-
controlled culdocentesis [16]. During the culdocentesis,
ascitic fluid was obtained from these patients for further
analysis.
The ascitic fluid was placed in a centrifuge tube on ice
and centrifuged at 400 × g for 10 minutes. Most of the
fluid was decanted, and the resulting pellet was sus-
pended with the remaining small amount of ascitic fluid
using a shaker. A smear was made according to the
usual procedures. The smear was fixed for 30 to 60 mi-
nutes in a 1/1 (v/v) mixture of ether and ethyl alcohol.
After dehydration, the smears were stained with
GIEMSA, evaluated by the Papanicolaou method [17]
and analysed in the Clinical Cytological Laboratory. The
samples were then analysed with visual light microscopy.
The presence of abnormal cells was based on the assess-
ment of the cellular shape (flat, sheet-like appearance
and well-defined borders) and nuclear and nucleolar size
differences in comparison to normal cells. The histo-
logical examination of the ovaries was carried out at the
Department of Pathology of the Clinical Centre of the
University of Pecs. The following cytologic grading sys-
tem was used: P I, no abnormal or atypical cells; P II,
atypical cells present, but with benign cytological ap-
pearance; P III, atypical cells suspicious for malignancy;
P IV, cells diagnostic for malignancy; and P V, a large
numbers of malignant cells.
Measurement of serum levels of tumour markers
Peripheral blood samples were obtained from patients
after the diagnosis of severe OHSS but before any inter-
ventions were performed. The serum concentrations of
CA-125 (Fujirebio Diagnostics, Malvern, PA, USA; Cata-
logue # 400–10, Lot # 29192) and HE4 (Fujirebio Diagnos-
tics; Catalogue # 404–10, Lot # 28374) were determined
by a quantitative sandwich enzyme-linked immunosorbent
assay (ELISA) according to the manufacturer’s protocol.
Serum concentrations were calculated with the Optima
2.10 R2 built-in data calculator software.
Risk for Ovarian Malignancy Algorithm (ROMA) index
The ROMA index is based on the serum levels of HE4
and CA-125 as measured by ELISA or calculated with
an Excel spreadsheet using pre-set formulas to generate
the predictive index (PI) for epithelioid ovarian cancer
according to the following equation for premenopausal
women: PI = −12 + 2.38 × ln [HE4] + 0.0626 × ln
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ROMA value (%) = exp (PI) / [1 + exp (PI)] × 100.
According to the manufacturer’s manual (Fujirebio Diag-
nostic Inc., Malvern, PA, USA), a ROMA index equal to
or greater than 13.1% is associated with a high risk of epi-
thelioid ovarian cancer in premenopausal women [18].
Results
Between January 2006 and December 2012, a total of
1,587 patients underwent OIT in 4,892 cycles at our IVF
clinic. Of these patients, 23 (1.4%) were hospitalized with
severe OHSS. We obtained follow-up data from 1,353
(85%) patients who underwent OIT and all 23 who de-
veloped OHSS. Of the 1,353 patients who underwent
OIT at our clinic and were followed-up in this study,
none developed a malignant ovarian tumour during the
study period. A review of the local institutional registry
revealed that none of the 462 registered patients with
malignant ovarian tumours had participated in our IVF
program.
Nine of the 23 patients who developed OHSS under-
went culdocentesis for severe OHSS. These patients
ranged in age from 23 to 34 years old (mean, 27.1 years).
Ascitic fluid was obtained from these patients for further
analysis. The cytological findings for these patients sug-
gested the presence of ovarian malignancy (Table 1) with
cytologic grades of P III and P IV in four cases each and
intermediate findings (P III - P IV) in one case (Figure 1).
None of the nine patients had ultrasonographic evidence
of a possible ovarian tumour before starting treatment;
therefore, we did not perform immediate surgical inter-
vention or histological sampling and elected to follow
the patients with supportive therapy.Table 1 Cytological, histological, and follow-up results, includ
and the ROMA index (%), for women with ovarian hyperstim




1 28 05/2006 CC + hMG + hCG P IV
2 23 03/2007 FSH + hMG + hCG P IV
3 24 10/2007 CC + FSH P IV
4 23 10/2007 CC + hCG P IV
5 26 11/2007 CC + FSH + hCG P III
6 30 02/2008 hMG + hCG P III
7 26 11/2008 FSH + hCG P III
8 30 11/2009 GnRH-a + hMG + hCG P III
9 34 10/2012 GnRH-a + FSH + hCG P III-IV
The dates of the Douglas puncture and control histology tests are shown.
OIT Ovarian induction therapy, CC Clomiphene citrate, hMG Human menopausal go
releasing hormone analogue, FSH Follicle-stimulating hormone.
*See Methods for a description of the cytologic stages P I-P V.
#Negative histology, normal ovarian tissue.
§Trigeminal pregnancy.
$Missed abortion.
The reference value for CA-125 is 0–39 U/ml and for HE4 is 0–150 pM.Figure 1 shows a photograph from a representative as-
piration from case no. 2, a 23-year-old woman who under-
went OIT in preparation for homologous insemination.
Cells sampled from the ascitic fluid were graded as P IV.
In all cases, the volume of the ovarian ascitic fluid grad-
ually decreased. To ensure that no malignancy existed, a
laparoscopic examination was performed at 8 to 12 weeks.
After close inspection of the abdominal cavity, eluents
from the Douglas pouch were sampled and histological
samples were obtained from the ovaries. All cytological
and histological tests of these follow-up examinations
were benign (Table 1). Follow-up laparoscopies were not
performed for these three patients, who were instead
followed clinically. During the follow-up period, none of
the nine patients displayed signs of an ovarian malignancy.
Peripheral blood serum levels of CA-125 and HE4
tumour markers were also evaluated for the nine pa-
tients with severe OHSS. The mean (± SD) value of CA-
125 was increased (105.81 ± 161.55 U/mL) compared to
the reference range of 0 to 39 U/mL. However, the mean
serum level of HE4 (42.89 ± 4.88 pM) was within the
normal range of 0 to 150 pM. The ROMA predictive
index was determined based on the concentrations of
these two tumour markers and the subject’s premeno-
pausal status. The ROMA index was very low (5.63% ±
1.24%), which indicated that the patients were not at a
high risk for developing ovarian malignancies (Table 1).
Discussion
Our data over a 6-year period indicate that there is no
relationship between OIT and subsequent malignant
ovarian tumour development among patients at our






HE4 (pM) ROMA (%)
06/2006, neg.# Tumor-free 45.2 40.1 4.9
05/2007, neg.# Tumor-free 27.1 47.9 7.0
12/2007, neg.# Tumor-free 505.8 38.2 5.0
12/2007, neg.# Tumor-free 40.5 39.9 4.8
02/2008, neg.# Tumor-free§ 19.2 51.6 8.1
04/2008, neg.# Tumor-free 9.8 45.6 5.2
01/2009, neg.# Tumor-free 38.1 45.2 6.2
01/2010, neg.# Tumor-free 56.3 37.4 4.2
12/2012, neg.# Tumor-free$ 210.3 40.1 5.3
nadotropin, hCG Human chorionic gonadotropin, GnRH-a Gonadotropin-
Figure 1 Cytologic examination of cells in the ascitic fluid of a patient with ovarian hyperstimulation and ultrasonographic assessment
of OHSS. On the left side (A,C) atypical cells can be observed among the leukocytes (Ly), red blood cells, mesothelial cells (Meso) and histiocytes
(Hi). Abnormal cells contain a dark cytoplasm that, in some places, resembles a seal-ring as well as large and rough-grained nuclei with multiple
nucleoli. Mitosis and polymorphonuclear (PMN) epithelial-like cells can be seen in the smear (B; magnification 200X). The cytologic diagnosis was
P IV: strong suspicion of an epithelial-like, malignant ovarian tumour. On the right side, three-dimensional (X,Y,Z; three orthogonal planes) Power
Doppler ultrasonographic visualization of the ovaries in a case of severe OHSS that demonstrates ominous signs of hypervascularization (static
3D image).
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of malignancy, these patients did not develop any evi-
dence of malignant ovarian tumours.
Because the risk of malignant ovarian tumours in is
higher in nulliparous women, greater vigilance is neces-
sary when treating this group. Bimanual examination
and vaginal ultrasonography are essential. The best
method to examine for enlarged ovaries is colour-
Doppler ultrasound. Rarely, laparoscopy or laparotomy
may be necessary. Therapy should only begin after
malignant ovarian tumours have been ruled out and/or
benign tumours have been removed.
Tumour markers, although useful, cannot differentiate
ovarian enlargement caused by overstimulation from en-
largement due to a malignancy. For example, the serum
CA-125 level closely correlates with the volume of the
ovary and is not indicative of the underlying pathology
[19]. Previous studies found no statistically significant
differences when comparing serum CA-125 levels
between spontaneous and stimulated cycles or between
pregnant and non-pregnant patients [20]. Longitudinal
follow-up of patients with sequential determinations of
their tumour markers may be helpful for an accurate
assessment. During the follow-up of patients with hyper-
stimulated ovaries, the serum concentration of the CA-
125 tumour marker declines and eventually normalizes. In
patients with malignant disease, the serum levels remain
elevated or gradually increase.
To overcome the relatively low specificity and sensitiv-
ity of risk assessment by a single tumour marker, Moore
et al. introduced the ROMA index as an accurate pre-
dictive index for ovarian cancer (76.4% sensitivity and96% specificity) [18]. Our results confirmed that the
single biomarker determination of CA-125 was not suffi-
cient to reliable evaluate ovarian malignancy in OHSS.
When the combination of CA-125 and HE4 was used,
despite the high levels of CA-125, HE4 remained under
the reference value and indicated no obvious signs of
malignancy. This observation was demonstrated by the
low ROMA scores (Table 1).
Epidemiologic follow-up data of infertile patients
demonstrates an increased life-long risk for high-grade
or borderline malignant ovarian malignancies. However,
the exact reason for this increased risk is unclear.
Whereas some authors believe it is a result of the infer-
tility itself [21], others suggest that ovulation induction
is associated with cancerogenesis [22,23]. Although
patients undergoing OIT may be at an increased risk of
developing ovarian tumours, studies have shown
reassuring results in terms of hormone treatment and
the incidence of invasive epithelial ovarian cancer [24].
However, exogenous hormone treatment is associated
with an increased risk of borderline ovarian malignancy
[25]. OIT has not been shown to increase the risk of
breast, uterine, or invasive ovarian cancers, although the
risk of borderline ovarian tumours might increase [26].
Moreover, the risk of cancer has been shown to be simi-
lar in children conceived by artificial reproductive ther-
apies and those conceived naturally [27]. It should also
be noted that, due to close medical surveillance, malig-
nancies are overdiagnosed in the female population; this
may also augment the early detection of cancers [28].
Our data suggest that even when the cytological evalu-
ation of ascitic cells obtained in patients diagnosed with
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radical surgical intervention is not clinically indicated.
Instead, these patients should be closely followed and
monitored. If the ovarian size remains abnormal, then
the aetiology of the enlargement should be determined
by histological sampling via laparoscopy, and the histolo-
gist should be informed of the previous OIT. Surgery
may still be required for abdominal bleeding, ovarian
torsion or rupture, or extra-uterine pregnancy.
Conclusions
We observed a minimal risk of ovarian malignancy shortly
after OIT at our IVF clinic. Large population-based studies
will be required to determine if ovarian induction is asso-
ciated with tumourigenesis over the long-term.
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